NCT03013543Phase 2Completed

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-03-01Actual
Enrollment · participants213Actual
Source updated2023-08-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview